Clinical trials: Intravenous Administration
Subarachnoid Hemorrhage
Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion.
- Trial name
- NCT04309708
- Testing
- Nimodipine pump infusion
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Pharmacokinetics
Hutrukin to Analyze Safety and PK in Healthy Volunteers
The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
- Trial name
- NCT05098080
- Testing
- Hutrukin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- XBiotech, Inc.
Solid Tumor Cancer
SB-743921 In Patients With Solid Tumors
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed.
- Trial name
- NCT00136513
- Testing
- SB-743921
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)
The purpose of this study is to determine approximately what percentage of an orally administered dose of PD-0332991 is absorbed from the gastrointestinal tract into the systemic circulation.
- Trial name
- NCT01802476
- Testing
- Oral Drug Formulation of PD-0332991, Intravenous Formulation of PD-0332991
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Fever
A New Formulation of Intravenous Paracetamol for Fever Management
The efficacy of intravenous paracetamol has never been compared with other drugs for the management of fever due to infections. Available data come from clinical studies conducted in healthy volunteers subject to experimental…
- Trial name
- NCT02283203
- Testing
- APOTEL max
- Where
- 6 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Non-Small Cell Lung Cancer
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC)…
- Trial name
- NCT01531790
- Testing
- Carboplatin, Pemetrexed, Endostar
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV) injection, and to evaluate efficacy on the basis of the changes seen in the cardiac biomarkers and continuous electrocardiography (ECG)…
- Trial name
- SUPPORT-1 (NCT00984802)
- Testing
- CMX-2043
- Where
- 5 sites in United States, India
- Volunteers
- 142 people
- Sponsor
- Ischemix, LLC
Neoplasms
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid…
- Trial name
- NCT01022853
- Testing
- BI 6727, BIBF 1120
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Cerebral Stroke, Ischemic Attack, Transient
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
- Trial name
- NCT00119626
- Testing
- NXY-059
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.
- Trial name
- GX-E2-P1 (NCT02291991)
- Testing
- GX-E2
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Advanced or Metastatic Solid Tumors
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting…
- Trial name
- Ulysse (NCT03316638)
- Testing
- W0101 - Cohort A1, W0101 - Cohort A2, W0101 - Expansion Phase
- Where
- 3 sites in France, Spain
- Volunteers
- 316 people
- Sponsor
- Pierre Fabre Medicament
Corona Virus Infection, Covid19
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
- Trial name
- AdMSCs (NCT05017298)
- Testing
- Allogeneic adipose-derived stem cells
- Volunteers
- 30 people
- Sponsor
- Celltex Therapeutics Corporation
Anemia
A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
This open label, single arm study will assess the efficacy for long-term maintenance of haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin beta [Mircera] in dialysis patients with chronic…
- Trial name
- NCT01156363
- Testing
- Dialysis, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 3 sites in Taiwan
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Jaundice, Obstructive
Remaxol® in Mechanical Jaundice of Non-malignant Origin
The purpose of this study is to assess the safety and efficacy of Remaxol (succinate + methionine + inosine + nicotinamide; POLYSAN Ltd., Russia) infusions at dose 400 and 800 ml to treat mechanical jaundice of non-tumor cause…
- Trial name
- NCT03418935
- Testing
- Remaxol (succinate + methionine + inosine + nicotinamide), Ringer's Solution
- Where
- 13 sites in Russia
- Volunteers
- 342 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Pain, Postoperative, Analgesia
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump
The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled analgesia (PCA) management systems: the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) and…
- Trial name
- NCT00264485
- Testing
- E-TRANS Fentanyl hydrochloride; Morphine
- Volunteers
- 799 people
- Sponsor
- Alza Corporation, DE, USA
IgG Deficiency, Infections
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency.
- Trial name
- Subklasse (NCT00522821)
- Testing
- intravenous immunoglobulins, antibiotics
- Where
- 9 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Prothya Biosolutions
Pre-diabetes
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
- Trial name
- NCT00312130
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants
The purpose of this study is to assess the safety and tolerability of guselkumab following single-dose intravenous (IV) infusion in Japanese healthy male participants.
- Trial name
- NCT03536325
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
- Trial name
- NCT00252382
- Testing
- SNS-595 Injection
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sunesis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.